Label Changes for:
Exforge (amlodipine and valsartan) Tablets
July 2008
Changes have been made to the BOXED WARNING, WARNINGS, PRECAUTIONS and PATIENT PACKAGE INSERT sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. |
| Sections Modified | Summary of Changes to Contraindications and Warnings |
|
BOXED WARNING
WARNINGS AND PRECAUTIONS
DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONS
PATIENT PACKAGE INSERT
|
BOXED WARNING WARNING: AVOID USE IN PREGNANCY WARNINGS AND PRECAUTIONS Fetal/Neonatal Morbidity and Mortality Exforge can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Drugs that act on the renin angiotensin system can cause fetal and neonatal morbidity and mortality when used in pregnancy. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death [see Use in Specific Populations (8.1)]. Hypotension ...Volume depletion should be corrected prior to administration of Exforge. Treatment with Exforge should start under close medical supervision... Impaired Renal Function - Hypertension ...As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may occur particularly in volume depleted patients... |

